AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma
Phase 3
Completed
- Conditions
- Recurrent Glioblastoma
- Interventions
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2016-12-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 423
- Registration Number
- NCT00777153
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Phase I Comparative Bioavailability Study
Phase 1
Active, not recruiting
- Conditions
- Solid Tumors
- Interventions
- Drug: AZD2281
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 197
- Registration Number
- NCT00777582
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2010-01-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 70
- Registration Number
- NCT00774553
- Locations
- 🇮🇳
Research site, Ahmedabad, India
🇺🇸Research Site, San Antonio, Texas, United States
Relative Bioavailability of Phase II and Phase III Formulations of AZD0530
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: AZD0530
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2009-06-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT00771979
- Locations
- 🇬🇧
Research Site, Alderley Park, United Kingdom
Assess Safety, Tolerability and PK of AZD3199 in Japanese
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: AZD3199 Turbuhaler®Drug: Placebo Turbuhaler®
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2009-05-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT00772759
- Locations
- 🇬🇧
Research Site, Slough, Berkshire, United Kingdom
A Project Ensuring Quality and Cooperation in the Chronic Obstructive Pulmonary Disease (COPD) Treatment
Completed
- Conditions
- COPDChronic Diseases
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 936
- Registration Number
- NCT00772733
- Locations
- 🇩🇰
Research Site, Viborg, Denmark
China Registration Study in Patients With Skin Infections
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2015-03-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 265
- Registration Number
- NCT00772447
- Locations
- 🇨🇳
Research Site, Qingdao, China
Hypertensive Treatment Pattern Survey for Type II Diabetes Mellitus Patients With Complication and Hypertension
Completed
- Conditions
- Hypertension
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2000
- Registration Number
- NCT00771069
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)
Phase 4
Completed
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Drug: GefitinibDrug: Placebo
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 296
- Registration Number
- NCT00770588
- Locations
- 🇨🇳
Research Site, Hangzhou, Zhejiang, China
Assess Pharmacokinetics, Safety and Tolerability in Healthy Chinese Volunteers After Oral Doses of Saxagliptin
Phase 1
Completed
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2009-07-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 34
- Registration Number
- NCT00770302
- Locations
- 🇨🇳
Research Site, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath